Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia.

about

Estimating the number of people who inject drugs in Australia.Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study

P2860

Q42368065-7BDA5003-2B59-46F5-BFDF-37D883BE1FBD Q56888804-54A49F92-3953-41EB-BB19-7D8118C59F1F

P2860

Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia.

Item

http://www.wikidata.org/entity/Q40450431

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Diversion and injection of bup ...... ost-introduction in Australia.

@en

type

Item

label

Diversion and injection of bup ...... ost-introduction in Australia.

@en

prefLabel

Diversion and injection of bup ...... ost-introduction in Australia.

@en

P1476

Diversion and injection of bup ...... post-introduction in Australia

@en

P2093

Briony Larance

http://www.w3.org/2001/XMLSchema#string

Ivana Kihas

http://www.w3.org/2001/XMLSchema#string

Nicholas Lintzeris

http://www.w3.org/2001/XMLSchema#string

Rebecca Jenkinson

http://www.w3.org/2001/XMLSchema#string

Richard Mattick

http://www.w3.org/2001/XMLSchema#string

Rosemary Cassidy

http://www.w3.org/2001/XMLSchema#string

P2860

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence

A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.

Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.

Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety.

The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations.

Monitoring risk: post marketing surveillance and signal detection.

The diversion and injection of a buprenorphine-naloxone soluble film formulation.

A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence.

Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.

Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.

P304

83-91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DAR.12344

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Louisa Degenhardt

Robert Ali

Nancy White

P577

2015-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26450513

http://www.w3.org/2001/XMLSchema#string

P921

Australia

Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia.

about

P2860

P2860

Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921